Core Viewpoint - Reap Bio announced a profit forecast for the first half of 2025, expecting a non-GAAP net profit of 180 million to 209 million yuan, representing a year-on-year growth of 30% to 50%, and a net profit attributable to shareholders of 240 million to 276 million yuan, indicating a growth of 50% to 70% [1][2]. Financial Performance - The net profit attributable to shareholders is projected to be between 244.16 million yuan and 276.72 million yuan, a growth of 50% to 70% compared to 162.78 million yuan in the same period last year [2]. - The non-GAAP net profit is expected to be between 181.75 million yuan and 209.72 million yuan, reflecting a growth of 30% to 50% from 139.81 million yuan in the previous year [2]. Business Growth Drivers - The company attributes its performance increase to four main factors: strategic partnerships with large breeding enterprises, focus on high-potential sectors like pet healthcare and overseas markets, operational efficiency improvements, and a robust management system [3][4]. - The pet healthcare segment is becoming a key growth driver, with significant revenue increases in new business areas [4][6]. Segment Performance - The pet supply chain business grew by 37.66% year-on-year, reaching 633 million yuan, accounting for 20.63% of total revenue [5]. - The pet biological products segment saw an impressive growth of 849.09%, achieving revenue of 37.44 million yuan, marking it as a standout performer [5]. Market Position and Strategy - Reap Bio has expanded its market presence by acquiring the Zhongrui supply chain platform, which now covers 7,000 pet hospitals and 3,400 pet stores across China [6]. - The company aims to enhance its product offerings and market penetration in the pet healthcare sector, focusing on building a comprehensive ecosystem that integrates research, validation, distribution, and service [9]. Future Outlook - The company plans to continue expanding its pet supply chain market coverage and revenue scale through capital operations and deepening product penetration in pet hospitals and stores [9]. - Despite the growth, the company acknowledges challenges such as increasing competition in the veterinary medicine market and the need for continuous innovation in product development [10].

上海澄明则正律师事务所 法律意见书 上海澄明则正律师事务所 关于绿康生化股份有限公司 致：绿康生化股份有限公司 上海澄明则正律师事务所（以下简称"本所"），接受绿康生化股份有限公司 （以下简称"公司"）的委托，指派本所律师出席公司 2025 年第二次临时股东会 （以下简称"《公 司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股东会 规则》（以下简称"《股东会规则》"）以及《绿康生化股份有限公司章程》（以下 简称"《公司章程》"）等规定出具《上海澄明则正律师事务所关于绿康生化股份 有限公司 2025 年第二次临时股东会之法律意见书》 （以下简称"本法律意见书"）。 本所律师按照中华人民共和国（以下简称"中国"，仅为本法律意见书之目 的，不包括香港特别行政区、澳门特别行政区和台湾地区）现行法律、法规的规 定对本次股东会的召集、召开程序是否合法及是否符合《公司章程》规定、出席 会议人员资格和股东会表决程序的合法有效性发表法律意见。 （以下简称"本次股东会"），并根据《中华人民共和国公司法》 本法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则本所律师愿 意承担相应的法律责任。 ...

Group 1 - The company expects a positive net profit for the first half of 2025, indicating an upward trend in performance [1][2] - The performance forecast period is from January 1, 2025, to June 30, 2025 [1] - The company has not yet audited the performance forecast by a registered accounting firm [1] Group 2 - The sales of the veterinary chemical drug segment have been strong, with increased sales of the main product, oxytetracycline, in both domestic and overseas markets [2] - The completion of the company's sixth-phase project has led to increased production capacity, meeting market demand and generating more profit [2] - The agricultural product processing segment has benefited from a decline in corn prices, contributing positively to overall performance [2]

Performance Forecast - The company expects a net profit of 127.43 million to 141.08 million yuan for the period from January 1, 2025, to June 30, 2025, representing a growth of 40% to 55% compared to the same period last year, where the profit was 91.02 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be between 117.83 million and 131.48 million yuan, an increase of 38.70% to 54.78% from last year's 84.95 million yuan [1] - Basic earnings per share are projected to be between 0.1651 yuan and 0.1828 yuan, compared to 0.1166 yuan in the previous year [1] Reasons for Performance Change - The sales of the veterinary chemical drug segment have continued to improve, with significant growth in both domestic and international markets, particularly in the overseas market [1] - The completion of the company's sixth-phase project has increased production capacity, ensuring supply for both domestic and international markets, which has contributed to higher profits [1] - The agricultural product processing segment has benefited from a decline in the price of corn, positively impacting overall performance [1]

Core Viewpoint - The recent private placement application by Huisheng Biological has been accepted by the Shenzhen Stock Exchange, but it faces significant criticism regarding the low issuance price and lack of specific investment projects, raising concerns about the interests of minority shareholders [1][2][3]. Company Summary - Huisheng Biological, a veterinary drug company, has been experiencing declining net profits since its IPO in 2020, with net profit dropping from 150 million yuan to a loss of 20.16 million yuan [6]. - The company's revenue has been increasing, but the net profit has been negatively impacted by the cyclical nature of the livestock industry and poor performance of previous investment projects [6][7]. - The company’s gross margin has decreased from 37% to 16.33%, and net margin has fallen from 19.31% to -1.65% due to various factors including declining product prices and rising costs [6]. Financing Details - The private placement will issue shares at a price of 9.19 yuan, significantly lower than the current market price of 20.68 yuan, which is only 44% of the market price [2][3]. - The maximum number of shares to be issued is 26,123,301, which could increase the controlling shareholders' stake to 47.92% [2][3]. - The total amount raised from this financing could reach 250 million yuan, but it is intended solely for replenishing working capital, raising questions about the necessity of the financing [3][4]. Investment Project Performance - Previous investment projects have largely failed to meet expected returns, with three out of five projects from the 2020 IPO not achieving their projected benefits [3][4]. - The company has faced challenges with its production capacity utilization and pricing, particularly in the case of the new products launched [4][6]. Industry Context - The veterinary drug industry is highly cyclical, with demand closely tied to the profitability of livestock farming [7]. - In the first quarter of 2024, Huisheng Biological reported a revenue increase of 92.96% and a net profit increase of 371.23%, attributed to improved cash flow in the livestock sector [7]. - However, the recent decline in pig prices raises uncertainty about whether the industry has truly recovered from its low point [7].

Core Viewpoint - The financial performance of Pulaike Company shows significant growth in revenue and net profit for the first quarter, indicating strong operational efficiency and profitability despite a decline in annual figures for 2024. Financial Performance Summary - For Q1, Pulaike's operating revenue reached 278.62 million yuan, an increase of 18.32% year-on-year [1] - The net profit attributable to shareholders was 52.91 million yuan, reflecting a 93.75% increase compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 48.90 million yuan, up 84.27% year-on-year [1] - The basic earnings per share were 0.16 yuan, doubling from 0.08 yuan in the previous year [1] - The net cash flow from operating activities was 46.90 million yuan, a significant turnaround from a negative cash flow of 4.39 million yuan in the previous year, marking a 1,167.15% increase [1] Profitability Metrics - The gross profit margin for the reporting period was 59.71%, down 4.70% year-on-year but up 4.19% quarter-on-quarter [2] - The net profit margin was 18.99%, which increased by 7.39% year-on-year and 23.78% quarter-on-quarter [2] Expense Management - Total expenses for the reporting period were 102 million yuan, a decrease of 15.73 million yuan compared to the previous year [2] - The expense ratio was 36.50%, down 13.37% year-on-year [2] - Sales expenses decreased by 2.09%, while management expenses saw a significant reduction of 44.70% [2] - Research and development expenses increased by 2.24%, and financial expenses rose by 63.81% [2] Annual Performance Overview - For the full year 2024, Pulaike reported an operating revenue of 1.043 billion yuan, a decline of 16.77% year-on-year [5] - The net profit attributable to shareholders was 92.81 million yuan, down 46.82% compared to the previous year [5] - The basic earnings per share for the year were 0.27 yuan [5] Company Background - Pulaike Company, established on June 22, 2002, specializes in the research, production, and sales of veterinary biological products, chemical drugs, and traditional Chinese veterinary medicine [5]

Core Viewpoint - The article discusses the significant transformation in the veterinary medicine industry in China, driven by the reduction and replacement of antibiotics in animal husbandry, alongside the rising demand for pet healthcare products, highlighting investment opportunities in the biological veterinary drug sector [3][4][5]. Group 1: Antibiotic Reduction and Replacement - The veterinary medicine industry is crucial for ensuring animal health and disease prevention, which in turn stabilizes the supply of meat and eggs [4]. - Historically, the industry relied heavily on antibiotics, leading to increased antibiotic resistance and environmental contamination [4][5]. - Since 2020, China has implemented strict regulations to phase out growth-promoting antibiotics, promoting the development of alternative products [5][6]. Group 2: Current Status of Biological Veterinary Drugs - Biological veterinary drugs, including vaccines and microbial preparations, are becoming essential for sustainable animal husbandry and food safety [6][7]. - Vaccines are the most significant category within biological veterinary drugs, preventing infectious diseases and reducing the need for antibiotics [6][7]. - The development of innovative veterinary drugs in China has lagged behind due to market preferences for cheaper, traditional solutions [8][9]. Group 3: Investment Dynamics - The rise of pet culture has led to increased investment in the veterinary drug sector, particularly in pet healthcare products [9][12]. - The Chinese pet medical market is projected to reach 94 billion yuan by 2024, indicating a growing focus on pet pharmaceuticals [9]. - Recent financing activities in the biological veterinary drug sector have primarily occurred in early to mid-stage investments, with significant interest in pet vaccines and alternative antibiotic products [12][13].

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has obtained a new veterinary drug registration certificate for "Prednisolone Tablets," marking a significant advancement in the treatment of canine allergic and inflammatory diseases [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug, "Prednisolone Tablets," is classified as a Category V new veterinary drug and is approved for treating allergic and inflammatory diseases in dogs, including non-specific eczema, summer dermatitis, and allergic conditions [2][3]. - The drug is developed by a consortium of companies, including Qingdao Weilan Biological Co., Ltd. and its subsidiaries, with a total research and development investment of 1.7444 million yuan [2][3]. Group 2: Market Background - Skin diseases have the highest incidence among pet diseases, particularly in dogs, with recurrent skin conditions accounting for over 75% of total incidence rates [2][3]. - There is a limited variety of drugs available for treating inflammatory skin diseases in pets, primarily relying on glucocorticoids, which have significant side effects and metabolic burdens [3][4]. Group 3: Drug Development and Impact - Prednisolone is a modified glucocorticoid with four times the anti-inflammatory activity of hydrocortisone and reduced sodium retention, making it suitable for animals with liver dysfunction [3][4]. - The approval of the new veterinary drug reflects the company's commitment to technological innovation and is expected to create new growth opportunities for the business [4].

2021年12月31日，回盛生物发布的创业板向不特定对象发行可转换公司债券上市公告书显示，本次发行 可转换公司债券募集资金总额为70,000.00万元(含发行费用)，扣除不含税发行费用的募集资金净额为 68,929.90万元。本次发行可转换公司债券募集资金扣除承销及保荐费855.66万元(不含税)的余额 69,144.34万元已由保荐机构(主承销商)于2021年12月23日汇入公司指定的募集资金专项存储账户中审众 环会计师事务所(特殊普通合伙)已进行验证，并出具了"众环验字(2021)0100097号"《验证报告》。回盛 生物此次的保荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代 表人为陈禹安、吴逸。 回盛生物于2020年8月24日在科创板上市，发行数量为2770万股，发行价格33.61元/股，保荐机构(主承 销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为张若思、金涛。 经计算，回盛生物上述两次募资共计16.31亿元。 中国经济网北京5月28日讯回盛生物（300871）(300871.SZ)近日披露2025年第一季度报告，报告期内， 该公司 ...

Group 1: Company Financials and Plans - The company currently has no share repurchase plan but will disclose any future plans in accordance with regulations [2] - As of May 20, 2025, the number of shareholders is 73,557 [3] - The company achieved a net profit of 148 million yuan in Q1 2025 and aims to meet its annual business targets [5] Group 2: Dividend and Profit Distribution - There is no mid-term dividend plan for 2025 as of now [2] - The profit distribution for 2024 will be implemented within two months after the annual shareholders' meeting [3] Group 3: Business Operations and Market Strategy - The company is focused on feed production, veterinary drug development, pig farming, and agricultural product processing, with no current plans to enter the pet economy [3] - The company plans to raise its pig output from 3.0285 million heads in 2024 to between 3.5 million and 4 million heads in 2025 [5] Group 4: Management and Incentive Policies - The increase in management expenses from 487 million yuan in 2023 to 560 million yuan in 2024 is due to depreciation from newly added fixed assets, not due to increased management salaries [3] - The company is reviewing its incentive policies to ensure they align with shareholder interests, especially in light of recent losses [6] Group 5: Market and Shareholder Communication - The company emphasizes value management through shareholding increases by major shareholders and improved governance and communication with investors [4] - The company is in the process of listing its pharmaceutical division on the Beijing Stock Exchange, with timelines dependent on regulatory reviews [5]